The most important part of the quote from Linda Powers at the Oppenheimer Healthcare Conference got cut off in my response to Doc. Anyway, it’s the second paragraph.
"Now this is the platform technology that I have explained. It is embodied into two key product lines, two major products. The first one that you see up there, DCVax-L, is for all types of operable tumors, and the second one is for all types of inoperable tumors. Both of the products use the same two key ingredients: that's the immune cell, the dendritic cells themselves, and the biomarkers of the tumor that we want the immune system to hit. The difference between the two products is just in how we get the biomarker ingredient. With the product for the operable tumors, when the tumor’s surgically removed in the operating room, they just drop the tissue in a kit and send the kit to us. It literally takes a couple minutes in the operating room. And then we process it and we get the biomarkers from that tumor tissue. Well for the inoperable tumors, we don't have the tumor tissue to get the biomarker, so instead we activate the dendritic cells in a little bit different way. We directly inject them into the tumor, in the body, and the dendritic cells pick up the biomarkers on-site, in the tumor, and from there on out they operate the same, to mobilize the immune system.
And that again brings up one of the key values and competitive strengths of our technology. Our technology, both products, the one for the operable tumors and the one for the inoperable tumors can apply to any patient. We are not limited by tumor characteristics and we're not limited by patient characteristics. So we can treat with the same product, made the same way, all of these diverse cancers. That also means that from a regulatory pathway standpoint, after we get the first approval, in the first cancer, each additional cancer is just a label extension. You're not starting all over again with the whole clinical trial pathway. "
